Silo Pharma, Inc. 8-K

What Happened Silo Pharma, Inc. (SILO) filed a Form 8-K on June 18, 2026 announcing that Nasdaq’s Listing Qualifications Staff has determined the company met the $1.00 minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq notified the company on June 17, 2026 that Silo’s common stock had closing bid prices at or above $1.00 for the period June 3, 2026 through June 16, 2026, and considers the matter closed. Silo had previously received a deficiency notice on June 27, 2025.

Key Details

• Nasdaq Listing Rule involved: 5550(a)(2) — $1.00 minimum closing bid price.
• Deficiency notice originally received: June 27, 2025.
• Nasdaq determination of compliance: June 17, 2026, based on closing bids at or above $1.00 from June 3–16, 2026.
• Company announcement: press release issued June 18, 2026 (attached as Exhibit 99.1 to the 8-K).

Why It Matters Regaining compliance with Nasdaq’s minimum bid price rule means Silo Pharma avoids potential delisting procedures tied to that specific deficiency. For investors, this reduces a short-term listing risk and preserves liquidity and trading on the Nasdaq exchange. This disclosure does not address other financial results or operational matters; investors should review the company’s other filings and disclosures for broader financial information.